Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 14, 2008. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by specific individuals through the Company's ShareReward Plan on January 10, 2008. The transactions occurred at a price of GBP 13.90 per share under the Dividend Reinvestment element of the Plan. The specific acquisitions were:
- Mr R M Bondy: 14 shares
- Mr E J Gray: 14 shares
- Mr J S Heslop: 14 shares
- Mr D Learmouth: 14 shares
- Dr D Pulman: 7 shares
- Mr C Viehbacher: 3 shares
- Mr A P Witty: 14 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares acquired by directors and connected persons under the ShareReward Plan.
- Confirm the transaction price of GBP 13.90 per share against the market price on January 10, 2008.
- Review the full terms of the ShareReward Plan entered into on October 5, 2001, to understand the Dividend Reinvestment mechanism.